In recent years, a novel biologic therapy with monoclonal antibodies against tumor necrosis factor-alpha has revolutionized the treatment of Crohn's disease. Infliximab, the first biologic agent, has been demonstrated to considerably improve both clinical and endoscopic outcomes. In view of the growing popularity of infliximab in the management of Crohn's disease, we review the profile of the a...

This article gives a comprehensive review of two-step single surgical alternative that searches to preserve the patient's cartilage and joint. It addresses knee from 360-degree perspective; First, articular side, full-thickness lesions are treated with hyaluronic acid (HA) scaffold combined bone marrow aspirate concentrate (BMC), which restores hyaline-like tissue. Then, deep inside subchondral...